Pfizer’s recent decision to discontinue the development of its twice-daily weight loss pill, danuglipron, highlights the ongoing challenges faced by pharmaceutical companies in creating effective and safe treatments for obesity. While obese patients in clinical trials experienced significant weight loss with the drug, the high rates of adverse side effects were a cause for concern.
0 Comments
The highly publicized “Take Care of Maya” trial concluded recently with a staggering $261 million verdict in compensatory and punitive damages for the Kowalski family. The jury held Johns Hopkins All Children’s Hospital of Florida responsible for various claims, including Beata Kowalski’s wrongful death by suicide, infliction of emotional distress, and false imprisonment and battery.
0 Comments
OpenAI, the creator of ChatGPT, has pushed back the release of its custom GPT store to early 2024, according to an internal memo obtained by Reuters. This development comes after the company’s initial plan to launch the store in November, which was announced during its first developer conference. The delay is attributed to OpenAI’s dedication
0 Comments